Show channels:
All channels
Bladder cancer
Brain and spinal
Breast cancer
Cervical
Colon & rectal
Dermatological
General Information
Gynecological
Head and Neck
Kidney/adrenal
Liver
Lung
Lymphoma
Multiple Myeloma
Myelodysplastic syndromes
Myeloproliferative disorders
Pancreas
Pediatric
Prostate
Sarcoma
Stomach
Testicular
Thyroid
Upper aerodigestive
Found 15757 articles
ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients
Overall, 33.9% of breast cancer population ADAM8-positive,
»
08/11/23
Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein
Elevated F11R expression in TNBC related with poorer survival prognosis.
»
08/11/23
Factors affecting adherence to a high-risk surveillance protocol among patients with Li-Fraumeni syndrome
Female sex found to be associated with longer duration of adherence.
»
08/11/23
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
On this regimen, TasQ blood levels 10-fold lower than optimal concentration.
»
06/15/23
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
Questions remain over optimal duration of therapy, predictive and prognostic biomarkers.
»
01/31/23
PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort.
Prognostic impact of PTPN11 variant also significant.
»
07/10/23
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs.
SLC0111 significantly improved therapy response of both wild-type and resistant GC cells.
»
04/27/23
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer.
Most HER2-amplified and HER2-low tumours showed homogeneous or mosaic HER2 expression pattern.
»
04/29/23
CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
Intracranial administration of allogeneic NKCs prolonged overall survival of xenograft brain tumor mice.
»
08/10/23
CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
Intracranial administration of allogeneic NKCs prolonged overall survival of xenograft brain tumor mice.
»
08/10/23
< Prev
Next >